This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Stocks in play: Resverlogix Corp.
Has entered into definitive transaction documents for the two-year extension of the Company's US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (and payment of accrued interest thereon), extending the maturity date to May 13, 2026. Resverlogix Corp. shares T.RVX are trading unchanged at $0.05.
